Nifty Pharma Dips, But Glenmark, Gland, and Biocon Defy the Downtrend with Strong Gains
By Shishta Dutta | Updated at: Jun 14, 2025 07:32 PM IST
Mumbai, June 13, 2025 – The Nifty Pharma index ended Friday’s session slightly in the red, slipping by 0.23% to close at 21,985.15, down 51 points from its previous close of 22,036.15. Despite showing some resilience earlier in the day, the index couldn’t hold onto its gains and ultimately fell, with 12 out of its 20 constituents seeing losses. The sector’s struggle highlights ongoing market volatility, even as a few stocks managed to buck the broader trend.
Index Snapshot
| Metric | Value |
|---|---|
| Previous Close | 22,036.15 |
| Open | 21,778.35 |
| Intraday High | 22,008.90 |
| Intraday Low | 21,742.05 |
| Close | 21,985.15 |
| Change (%) | -0.23% |
| 52-Week High | 23,907.90 |
| 52-Week Low | 19,121.10 |
| 30-Day Change | +3.17% |
| 1-Year Change | +11.64% |
| Traded Volume | 2.19 Cr shares |
| Traded Value | ₹2,533.43 Cr |
Top Gainers in Nifty Pharma
| Company | Close (₹) | Change (₹) | Change (%) |
|---|---|---|---|
| Glenmark | 1,674.00 | +34.40 | +2.10% |
| Gland Pharma | 1,690.00 | +20.60 | +1.23% |
| Biocon | 356.50 | +4.25 | +1.21% |
| Cipla | 1,507.80 | +5.00 | +0.33% |
| Alkem Labs | 4,850.50 | +4.00 | +0.08% |
Notable Laggards
| Company | Close (₹) | Change (₹) | Change (%) |
|---|---|---|---|
| Ajanta Pharma | 2,632.70 | -97.60 | -3.57% |
| Granules India | 508.10 | -15.80 | -3.02% |
| Lupin | 1,997.80 | -25.40 | -1.26% |
| JB Chemicals | 1,724.00 | -21.30 | -1.22% |
| Ipca Labs | 1,368.00 | -15.00 | -1.08% |
Index Technical Positioning
- The index is currently 8% below its 52-week high and 15% above its 52-week low, indicating moderate recovery momentum but lacking fresh breakout triggers.
- Short-term breadth remains mixed with recent 30-day gains of 3.17%, supported by select stocks like Laurus Labs (+0.25%) and Glenmark (+34.40%).
Market Breadth
Out of 20 index constituents:
- 8 advanced
- 12 declined
- 0 remained unchanged
Sector Outlook
While select pharma stocks like Glenmark and Gland Pharma showed relative strength amid broader selling pressure, the sector remains sensitive to global regulatory updates and USFDA actions. Investor focus may remain on upcoming earnings guidance, API pricing trends, and clinical progress across generics and biosimilars.
About Nifty Pharma:
The Nifty Pharma index is a benchmark NSE index tracking the performance of 20 top pharmaceutical companies listed in India. It includes diversified players across formulations, APIs, and biotechnology segments. The index is a barometer of healthcare market sentiment and global export dynamics.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
